Consumer Staples [ 12/12 ] | Personal Care Products [ 64/75 ]
NASDAQ | Common Stock
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS).
Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death.
The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017.
Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 5, 24 | -0.05 Increased by +56.67% | -0.08 Increased by +35.00% |
| Aug 8, 24 | -0.07 Increased by +46.15% | -0.06 Decreased by -16.67% |
| Apr 1, 24 | -0.08 Increased by +83.33% | -0.10 Increased by +20.00% |
| Feb 14, 24 | -0.08 Increased by +82.61% | -0.10 Increased by +20.00% |
| Dec 8, 23 | -0.12 Increased by +76.47% | -0.23 Increased by +47.83% |
| Aug 10, 23 | -0.13 Increased by +53.57% | -0.20 Increased by +35.00% |
| May 11, 23 | -0.48 Decreased by -166.67% | -0.33 Decreased by -45.45% |
| Feb 9, 23 | -0.46 Decreased by -475.00% | -0.38 Decreased by -21.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 3.95 M Increased by +18.34% | -10.97 M Decreased by -273.72% | Decreased by -277.42% Decreased by -246.80% |
| Mar 31, 24 | 4.14 M Decreased by -37.21% | -10.03 M Increased by +74.16% | Decreased by -242.45% Increased by +58.84% |
| Dec 31, 23 | 2.14 M Decreased by -14.64% | -8.28 M Increased by +77.54% | Decreased by -386.60% Increased by +73.68% |
| Sep 30, 23 | 3.86 M Increased by +49.19% | -23.77 M Increased by +42.06% | Decreased by -615.43% Increased by +61.16% |
| Jun 30, 23 | 3.34 M Decreased by -65.20% | 6.31 M Increased by +128.45% | Increased by +188.98% Increased by +181.76% |
| Mar 31, 23 | 6.59 M Decreased by -49.45% | -38.79 M Decreased by -173.62% | Decreased by -589.02% Decreased by -441.27% |
| Dec 31, 22 | 2.51 M Decreased by -82.26% | -36.84 M Decreased by -477.46% | Decreased by -1.47 K% Decreased by -3.15 K% |
| Sep 30, 22 | 2.59 M Decreased by -83.46% | -41.02 M Decreased by -855.24% | Decreased by -1.58 K% Decreased by -5.67 K% |